Stockscreener 앱 받기
4.67
1.08%
0.05
전일 마감가:
$4.62
열려 있는:
$4.58
하루 거래량:
391.12K
Relative Volume:
0.41
시가총액:
$681.51M
수익:
$389.42M
순이익/손실:
$30.70M
주가수익비율:
22.86
EPS:
0.2043
순현금흐름:
$67.23M
1주 성능:
+1.74%
1개월 성능:
-0.21%
6개월 성능:
+15.88%
1년 성능:
-32.51%
1일 변동 폭
$4.58
$4.695
1주일 범위
$4.475
$4.695
52주 변동 폭
$3.025
$7.97
Mimedx Group Inc Stock (MDXG) Company Profile
명칭
Mimedx Group Inc
전화
(770) 651-9100
주소
1775 W OAK COMMONS COURT, NE, MARIETTA
Compare MDXG vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDXG
Mimedx Group Inc
|
4.67 | 681.51M | 389.42M | 30.70M | 67.23M | 0.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mimedx Group Inc Stock (MDXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-23 | 개시 | Citizens | Mkt Outperform |
| 2024-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-07 | 개시 | Lake Street | Buy |
| 2023-10-27 | 개시 | Craig Hallum | Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-07-26 | 개시 | Northland Capital | Outperform |
| 2021-03-19 | 개시 | H.C. Wainwright | Buy |
모두보기
Mimedx Group Inc 주식(MDXG)의 최신 뉴스
MiMedx Group stock gained 1.54 percent on October 6 - AD HOC NEWS
Sanara MedTech Shareholders Approve Merger with MiMedx - The Globe and Mail
What's Driving the Buzz Around MiMedx Group, Inc. (MDXG) in Healthcare Stocks? - Kalkine Media
What Does the AXIOFILL Court Ruling Mean for MiMedx (NASDAQ:MDXG)? - Kalkine Media
MiMedx Group: Court Remands Both Matters to FDA for Further Consideration Consistent With Order >MDXG - Moomoo
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter - Investing News Network
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter - globenewswire.com
U.S. District Court Orders FDA to Reclassify MiMedx Wound Powder as Device - Lawxy AI
FDA Must Revisit MiMedx Wound Care Powder Classification - Law360
FDA Must Revisit MiMedx Wound Care Powder Classification - Law360
MiMedx Group, Inc (MDXG) Stock Analysis: Exploring a 53.85% Potential Upside in Biotechnology - DirectorsTalk Interviews
MiMedx Group stock steadies as investors look to upcoming catalysts - AD HOC NEWS
MiMedx Group (MDXG) Holds Steady at $4.76 as Traders Eye $5.00 ResistanceMerger Arbitrage - careplusvn.com
Two New York conferences will include MIMEDX executives on Sept. 9 and 10 - Stock Titan
MIMEDX GROUP, INC. SEC Filing (Sep 8, 2026) - stocktitan.net
MIMEDX to Participate in Upcoming Investor Conferences - Yahoo Finance
MIMEDX to Participate in Upcoming Investor Conferences - GlobeNewswire
Sanara MedTech Seeks Shareholder Approval for Merger With MiMedx - The Globe and Mail
MDXG Should I Buy - Intellectia AI
MiMedx Group (NASDAQ: MDXG) readies shares for business combination - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc.MDXG - Eastern Progress
Sanara MedTech (SMTI) agrees to MiMedx takeover, targeting year-end close - Stock Titan
MiMedx (MDXG) Earnings Metrics: The Bottom-Line Figure Trails Its Comparison at the Close; Immediate Response: Shares Move 3.58% Up on the DayEnergy Earnings Report - vinanet.vn
MDXG Q2 2026 Earnings: Wider-than-Expected Loss as EPS Misses Estimates by 106%Post-Announcement Reaction - vinanet.vn
Tranche Update on MiMedx Group, Inc.'s Equity Buyback Plan announced on February 25, 2026. - marketscreener.com
MiMedx Group (SMTI partner) clarifies Sanara merger fees and $33 cash-plus-stock deal - Stock Titan
Sanara MedTech Corrects Termination Fees in Merger Deal with MiMedx - Kalkine Media
Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock merger terms and corrects fees - Stock Titan
Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock per share in merger - Stock Titan
MiMedx Group, Inc (MDXG) Stock Report: Exploring a 63.93% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
MiMedx Group Inc (MDXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MiMedx Group, Inc Revenue Breakdown – NASDAQ:MDXG - TradingView
MiMedx Group (MDXG) Climbs 3.83% to $4.34, Approaching Key Resistance LevelSpring Pattern - vinanet.vn
MiMedx (MDXG) Q2 2026 Earnings Call Transcript - AOL.com
MiMedx Group Inc (MDXG) Stock News Today - TradingKey
MiMedx (MDXG) Q2 2026 Earnings Call Transcript - The Globe and Mail
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Are Actually Better Than They Appear - simplywall.st
Lazard Asset Management LLC Sells 264,718 Shares of MiMedx Group, Inc $MDXG - MarketBeat
MiMedx Group (MDXG) Holds Steady Near $4.24 as Consolidation ContinuesExtension Target - vinanet.vn
MiMedx Group (NASDAQ:MDXG) Stock Price Up 7.8%What's Next? - MarketBeat
Renaissance Technologies LLC Has $11.93 Million Stake in MiMedx Group, Inc $MDXG - MarketBeat
Wall Street Zen Downgrades MiMedx Group (NASDAQ:MDXG) to Sell - MarketBeat
Mimedx to buy Sanara for $350M to move beyond wound care - bioworld.com
MiMedx to Buy Sanara MedTech for $350M - Medical Product Outsourcing
MiMedx Group, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiMedx to acquire Sanara MedTech for $350M - MassDevice
MiMedx Group: Sanara Deal Comes At A Poor Time - Seeking Alpha
MiMedx Group affirms FY26 sales guidance of $260-290M - scanx.trade
MiMedx Group Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
MiMedx Group Q2 Earnings Call Highlights - tradingview.com
Mimedx Group Inc (MDXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mimedx Group Inc 주식 (MDXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hulse William Frank IV | General Counsel and CAO |
Mar 10 '26 |
Option Exercise |
4.50 |
136,364 |
613,638 |
624,900 |
| DOUG RICE | Chief Financial Officer |
Mar 10 '26 |
Option Exercise |
4.50 |
243,000 |
1,093,500 |
508,678 |
| Maersk-Moller Kimberly | Chief Commercial Officer |
Nov 06 '25 |
Sale |
7.42 |
58,300 |
432,329 |
236,982 |
| Kimberly Ann Maersk-Moller | Officer |
Nov 06 '25 |
Proposed Sale |
7.33 |
68,587 |
502,743 |
0 |
0.00%
자본화:
|
볼륨(24시간):